Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close
The profile picture for Angela Wandinger-Ness

Angela Wandinger-Ness

►

Profile

Profile

  • Organization
    University of New Mexico Health Sciences Center

  • Use Statement - Please enter your reason for creating an NCI Hub account.
    (not set)

  • Employment Status
    (not set)

  • Website
    (not set)

  • Telephone
    (not set)

  • Reason
    Using as background for my research

  • Interests
    1. cancer biology
    2. cancer immunotherapy
    3. GTPases
    4. Humanized Mice
    5. ovarian cancer
    6. therapeutic

  • Biography
    An expert in cell biology and protein biochemistry, Dr. Wandinger-Ness has been studying the roles of GTPases in membrane trafficking, cell adhesion and cancer for nearly 30 years. Dr. Wandinger-Ness and a team of basic and physician scientists have targeted the Rac1 pathway for cancer patient benefit and identified a lead candidate, R-ketorolac, and ovarian cancer as a first indication. Collaborative publications show that R-ketorolac inhibits Rac1 activity in cells, and in animal models the drug minimizes tumor cell dissemination, implantation, and invasion of peritoneal tissues and organs. Dr. Wandinger-Ness is recognized via a 2019 STC Innovation Fellow Award for the work establishing R-ketorolac as an effective inhibitor of the activity of Rac1 and Cdc42 GTPases in ovarian cancer cells and impact of administration of the clinically approved racemic drug in improved ovarian cancer patient survival.